Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 1
1997 1
1998 1
2000 2
2002 1
2003 1
2004 3
2005 3
2006 1
2007 1
2008 3
2009 10
2010 17
2011 12
2012 16
2013 13
2014 17
2015 17
2016 18
2017 13
2018 14
2019 26
2020 21
2021 19
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

212 results
Results by year
Filters applied: . Clear all
Page 1
Pan-cancer whole-genome analyses of metastatic solid tumours.
Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Priestley P, et al. Among authors: van herpen cml. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23. Nature. 2019. PMID: 31645765 Free PMC article.
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. Uijen MJM, et al. Among authors: van herpen cml. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 34120192 Free PMC article. Review.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Banerji U, et al. Among authors: van herpen cml. Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27. Lancet Oncol. 2019. PMID: 31257177 Clinical Trial.
Merkel Cell Carcinoma: New Trends.
Zwijnenburg EM, Lubeek SFK, Werner JEM, Amir AL, Weijs WLJ, Takes RP, Pegge SAH, van Herpen CML, Adema GJ, Kaanders JHAM. Zwijnenburg EM, et al. Among authors: van herpen cml. Cancers (Basel). 2021 Mar 31;13(7):1614. doi: 10.3390/cancers13071614. Cancers (Basel). 2021. PMID: 33807446 Free PMC article. Review.
[Salivary gland carcinoma].
Lassche G, van Engen-van Grunsven ACH, Honings J, Dijkema T, Weijs WLJ, van Herpen CML. Lassche G, et al. Among authors: van herpen cml. Ned Tijdschr Geneeskd. 2020 Jul 16;164:D4760. Ned Tijdschr Geneeskd. 2020. PMID: 32779918 Dutch.
Toxicity-induced modification of treatment: what is in a name?
Kok DE, Winkels RM, van Herpen CM, Kampman E. Kok DE, et al. Among authors: van herpen cm. Eur J Cancer. 2018 Nov;104:145-150. doi: 10.1016/j.ejca.2018.09.018. Epub 2018 Oct 20. Eur J Cancer. 2018. PMID: 30352382 Review.
Theranostic applications of antibodies in oncology.
Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC. Fleuren ED, et al. Among authors: van herpen cm. Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21. Mol Oncol. 2014. PMID: 24725480 Free PMC article. Review.
Kidney injury during VEGF inhibitor therapy.
den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen CM. den Deurwaarder ES, et al. Among authors: van herpen cm. Neth J Med. 2012 Aug;70(6):267-71. Neth J Med. 2012. PMID: 22859418 Free article. Review.
212 results